Underbayev, Chingiz

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 341

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Landau, D. A., Sun, C., Rosebrock, D., Herman, S. E. M., Fein, J., Sivina, M., Underbayev, C., Liu, D., Hoellenriegel, J., Ravichandran, S., et al. (2017) · Nature Communications

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 176

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Robinson, H. R., Qi, J., Cook, E. M., Nichols, C., Dadashian, E. L., Underbayev, C., Herman, S. E. M., Saba, N. S., Keyvanfar, K., Sun, C., et al. (2018) · Blood

Chronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 108

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Zhang, D., Harris, H. M., Chen, J., Judy, J., James, G., Kelly, A., McIntosh, J., Tenn-McClellan, A., Ambing, E., Tan, Y. S., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 35

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Alsadhan, A., Chen, J., Gaglione, E. M., Underbayev, C., Tuma, P. L., Tian, X., Freeman, L. A., Baskar, S., Nierman, P., Soto, S., et al. (2023) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 23